GlassScriptPhysician profile
Amanda Hutson
NPI 1184012098
$2,560.25
in general payments reported to CMS, 2019-2025
29 companies · $857 in 2025
The $857 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $173 · 2023: $400 · 2024: $1,011 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $15.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.38 |
| Education | $15.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.82 | 2023-2025 | |
| Janssen Biotech, INC. | $349.44 | 2024-2025 | Tremfya, Stelara, Remicade |
| Alexion Pharmaceuticals, INC. | $266.19 | 2022-2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $190.38 | 2021-2023 | Fasenra |
| Lilly USA, LLC | $140.87 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $125.29 | 2024-2025 | Ibsrela |
| Breas Medical, INC. | $93.32 | 2025 | Vivo 45 Ls, Clearo, Human Design Medical |
| Grifols USA, LLC | $84.75 | 2022 | |
| Aimmune Therapeutics, INC. | $84.04 | 2024-2025 | Zenpep |
| Pfizer INC. | $74.18 | 2021-2023 | |
| Celltrion USA INC. | $72.60 | 2024-2025 | Vegzelma, Zymfentra |
| Madrigal Pharmaceuticals | $72.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $69.07 | 2024-2025 | Eohilia, Entyvio |
| Phathom Pharmaceuticals, INC. | $62.37 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $49.92 | 2024 | Dificid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $38.39 | 2024-2025 | Dupixent |
| Genzyme Corporation | $34.56 | 2024-2025 | |
| Organon LLC | $33.61 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.53 | 2024-2025 | Xifaxan |
| Csl Behring | $28.08 | 2023 | Kcentra |
| Janssen Pharmaceuticals, INC | $24.70 | 2021 | |
| Mauna Kea Technologies, INC. | $23.95 | 2025 | |
| Daiichi Sankyo INC. | $21.65 | 2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $20.05 | 2024 | Simlandi |
| Ipsen Biopharmaceuticals, INC | $18.88 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $18.68 | 2024 | Sutab, Suflave |
| Alcresta Therapeutics, INC. | $14.57 | 2024 | Relizorb |
| Intercept Pharmaceuticals, INC. | $13.84 | 2024 | |
| Echosens North America, INC. | $10.12 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hutson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.